Investor Presentaiton
Investor presentation
Full year 2018
Slide 11
Biopharm strategy focus on in-market execution as well as
internal and external innovation
DKK
Broadly unchanged biopharm sales driven by
Norditropin® and NovoEight®
million
Local currency growth
-1%
-11%
26%
NA
7%
-11%
500
Haemophilia care
250
0
-250
-500
-750
-1,000
Total
Novo- Novo- Other
SevenⓇ Eight®
haemo-
philia
Nordi- Other
tropinⓇ biopharm
'Return to growth' strategy on track
Succeeded in-market despite competition in the inhibitor
segment: Updated NovoSevenⓇ label for surgical use and
global focus on acquired haemophilia treatment as well as solid
sales growth for NorditropinⓇ and NovoEight®
Progressing pipeline with global launch of Refixia®; expected
approval of N8-GP; expected filing of NovoEight® in China; and
pipeline advancement with concizumab and with somapacitan
in both GHD and AGHD
Adding complementary assets with the in-licensing of
EpiDestiny's product for sickle cell disease and acquisition of
the North American rights to Macrilen TM, the first oral product
for diagnosis of AGHD
Other haemophilia comprises NovoThirteenⓇ and Refixia®, 'Other biopharm' comprises primarily
Vagifem® and Activelle®
GHD: Growth hormone deficiency; AGHD: Adult growth hormone deficiency
Note: Rexifia® is the global brand name and RebinynⓇ is the brand name in North AmericaView entire presentation